Health Care·Biotechnology·$79.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $11.56 | N/A | +29.47% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $11.56 | N/A | +29.47% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, they did not provide specific revenue figures or future guidance.
We are pleased with our EPS performance this quarter.
Our focus remains on innovation and delivering value to patients.
Regeneron's strong EPS performance, exceeding expectations by nearly 30%, led to a positive stock reaction, with shares rising 1.29%. The lack of revenue data and guidance leaves some uncertainty, but the management's optimistic tone suggests confidence in future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ON SEMICONDUCTOR COR
Jul 29, 2024